Company Profile
Sperogenix Therapeutics, founded in 2019, is a platform focusing on development and commercialization of rare disease drugs in China , with a focus on pediatric genetic diseases and neurological diseases, providing clinically accessible products for rare disease patients and successful commercial solutions for rare disease therapeutics in China. Company is incorporated in Hong Kong, with renowned investors such as Lilly Asia Ventures, Morningside Ventures and Prosperico Venture.
Investment Highlights:
- Rapid product commercialization advancement, with a pipeline focusing on pediatric genetic diseases and neurological diseases, where there are strong demands in China. 2024 will be the first year of commercialization for the Company
- Vamorolone, with great commercialization potentials, is positioned to be the “Best-in-Class” oral therapy for DMD
- Building the leading platform for rare disease therapeutics with high clinical accessibility in China
- Strong leadership team with in-depth experience in clinical transformation and the commercialization of rare disease in China
- Promising financial outlook, with the goal to generate scaled revenues in 2024, turn profitable in 2026 and achieve RMB 1bn in revenue in 2028
Corporate Speaker
Alan Yan
Founder & CEO
Alan Yan, the Founder and CEO of Sperogenix Therapeutics, has 25 years+ of senior management experience in MNC. He served as the head of Sanofi Pasteur‘s business operations in China, first General Manager of Actelion China, and held multiple senior management positions in Sandoz China and Merck KGaA China. Alan’s management experience covers clinical & regulatory development, portfolio & strategy, BD, sales and marketing, as well as commercial channel management and operations. Alan has received his medical degree in Shanghai Medical University in 1993, and afterwards practiced in the cardiology department of Shanghai Zhongshan Hospital